PRESS RELEASES More events are coming soon. Keyword Search Year: 20202019201820172016201520142013 11/23/20 Summary ToggleTRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment Printer Friendly PDF Version 11/16/20 Summary ToggleTRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines Printer Friendly PDF Version 11/10/20 Summary ToggleTRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update Printer Friendly PDF Version 11/03/20 Summary ToggleTRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020 Printer Friendly PDF Version 10/26/20 Summary ToggleTRACON Announces FDA Orphan Drug Designation for TRC102 in Malignant Glioma, Including Glioblastoma Printer Friendly PDF Version 09/21/20 Summary ToggleTRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer Printer Friendly PDF Version 09/10/20 Summary ToggleTRACON Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Printer Friendly PDF Version 09/03/20 Summary ToggleTRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference Printer Friendly PDF Version 08/31/20 Summary ToggleTRACON Pharmaceuticals Announces Additional $5.0 Million Private Placement Printer Friendly PDF Version 08/27/20 Summary ToggleTRACON Pharmaceuticals Announces $5.0 Million Private Placement Printer Friendly PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
